<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16565">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01817309</url>
  </required_header>
  <id_info>
    <org_study_id>BLPS</org_study_id>
    <nct_id>NCT01817309</nct_id>
  </id_info>
  <brief_title>Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis</brief_title>
  <official_title>Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <authority>Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peritoneal dialysis (PD) is the first-line treatment of end stage renal disease (ESRD) in
      Hong Kong. Despite the advances in antibiotic therapy and connecting system, recurrent
      peritonitis remains the major cause of peritoneal failure. A reliable predictor of relapsing
      peritonitis is invaluable in the management of PD peritonitis. Recent studies showed that
      bacterial-derived lipopolysaccharide (LPS) fragments are present in clinically used fluids
      such as dialysis fluid. LPS are thought to be derived from microorganisms inhabiting body
      fluid. The investigators hypothesize that the presence of LPS in PD effluent is a predictor
      of relapsing peritonitis in PD patients. The investigators plan to study 300 patients with
      PD peritonitis. After inform consent, specimens of PD effluent will be collected on the day
      of initiating antibiotic treatment, every 5 days until the day of completing antibiotic
      treatment, and then 28 days later for the test of LPS level. All patients will be followed
      for one year after completion of antibiotic therapy for the development of relapsing,
      recurrent, or repeat peritonitis episodes. Our study would explore the use of detecting LPS
      in PD effluent as a non-invasive tests for the prediction of relapsing peritonitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>relapsing peritonitis</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Relapsing peritonitis will be defined as an episode that occurs within 4 weeks of completion of therapy of a prior episode with the same organism (or culture negative in the second episode).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>recurrent peritonitis</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Recurrent peritonitis will be defined as an episode that occurs within 4 weeks of completion of therapy of a prior episode but with a different organism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>repeat peritonitis</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Repeat peritonitis will be defined as an episode that occurs more than 4 weeks after completion of therapy of a prior episode with the same organism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>conversion to long-term hemodialysis</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>peritonitis that requires hospitalization</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>catheter removal</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death due to peritonitis</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Peritoneal Dialysis Associated Peritonitis</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>endotoxin assay in peritoneal dialysis effluent</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>endotoxin assay in peritoneal dialysis effluent</intervention_name>
    <description>endotoxin level by Limulus Amebocyte Lysate (LAL) assay</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        at least two of the followings:

          1. abdominal pain or cloudy PD effluent;

          2. leukocytosis in PD effluent (WBC &gt; 100/ml); and

          3. positive Gram-stain or culture from PD effluent

        Exclusion Criteria:

          -  mycobacterial peritonitis

          -  obvious surgical problems and require laparotomy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheuk Chun Szeto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheuk Chun Szeto, MD</last_name>
    <phone>852-2632-3878</phone>
    <email>ccszeto@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bonnie CH Kwan, MBBS</last_name>
    <phone>852-2632-3528</phone>
    <email>bonniekwan@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Medicine, Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheuk Chun Szeto, MD</last_name>
      <phone>852-2632-3878</phone>
      <email>ccszeto@cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Bonnie CH Kwan, MBBS</last_name>
      <phone>852-2632-3528</phone>
      <email>bonniekwan@cuhk.edu.hk</email>
    </contact_backup>
    <investigator>
      <last_name>Cheuk Chun Szeto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 15, 2013</lastchanged_date>
  <firstreceived_date>March 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Cheuk-Chun SZETO</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>renal failure</keyword>
  <keyword>survival</keyword>
  <keyword>peritoneal failure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
